SCHEMBL4148973

SCHEMBL4148973

C[C@@H]1CN(Cc2ccc(O)cc2)C[C@H](C)O1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 2/20 0.50
CYP2A13 Q16696 1/20 0.50
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
HRH4 Q9H3N8 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
AGTR1 P30556 1/20 0.47
AGTR2 P50052 1/20 0.47
POLB P06746 1/20 0.47
SIGMAR1 Q99720 2/20 0.44
ALDH1A1 P00352 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
DRD2 P14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4148981 1.00 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL3744757 0.86 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL12383 0.84 ALDH1A1 (0.55) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL12156566 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL22711368 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL9390979 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL578456 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL578799 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL5101706 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA
SCHEMBL9163392 0.82 KDM4E (0.53) KDM4EHTTTDP1CYP2A13LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118282-A1 Compounds and methods for treatment of amyloid-beta-peptide related disorders EXONHIT THERAPEUTICS SA (FR) 2009-05-07 US disclosed
US-20090118282-A1 Compounds and methods for treatment of amyloid-beta-peptide related disorders EXONHIT THERAPEUTICS SA (FR) 2009-05-07 US disclosed
US-20090118282-A1 Compounds and methods for treatment of amyloid-beta-peptide related disorders EXONHIT THERAPEUTICS SA (FR) 2009-05-07 US disclosed
WO-2007034329-A2 COMPOUNDS AND METHODS FOR TREATMENT OF AMYLOID-BETA-PEPTIDE RELATED DISORDERS EXONHIT THERAPEUTICS SA (FR) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118282-A1 Compounds and methods for treatment of amyloid-beta-peptide related disorders APP, BACE1, IAPP KDM4E 3874/4885HTT 33/4885TDP1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.